Elgan Pharma is a late clinical stage neonatology-focused biopharmaceutical company, dedicated to developing therapies for preterm infants and neonates.
Compassionate Innovation for Preterm Infants
Premature births are the number one cause of newborn deaths worldwide. As the standard of care improves, survival rates of premature infants are increasing and today babies born very premature are likely to survive in developed countries. However, there are many short- and long-term prematurity associated complications, with the youngest babies at highest risk of a serious and often life-threatening event that can lead to lifelong disabilities. There is a great need for solutions that improve health outcomes and quality of life of these babies and their families.
Complications associated with premature birth can also lead to longer hospitalization and increased burden for healthcare systems.
Elgan Pharma has multiple promising clinical-stage and preclinical investigational therapeutics, including two leading clinical programs- ELGN-GI and ELGN-EYE. Both therapies address high unmet medical needs of preterm infants with no existing solutions to date.
ELGN-GI promotes a faster maturation of the infants' intestines, allowing them to rapidly reach full enteral feeding and become independent from parenteral nutrition, while minimizing serious complications and reducing burden for healthcare systems. The treatment completed several clinical trials including a successful Phase III study and recently started a second Phase III.
ELGN-EYE is a local drug targeted at preventing vision impairment due to retinopathy of prematurity (ROP)-a condition that occurs because of underdeveloped blood vessels in the eyes of premature babies at the time of birth. ROP is the leading cause of blindness in children worldwide. Phase I study with the therapy was successfully concluded and Phase II will commence shortly.
Our Values and Code of Ethics
At Elgan Pharma, our focus is on improving the lives of preterm infants. Our research and development efforts are dedicated to providing the highest standard of care. We are driven by innovation, a commitment to quality, and a deep understanding of the challenges faced by vulnerable members of society.
Merit-Based Diversity, Equity, and Inclusion
At Elgan Pharma, we believe that everyone has something valuable to offer. We recognize that diverse teams enhance collaboration, foster a broader range of perspectives, and reflect the global communities we serve. Within our organization, we aim to create an environment where everyone is respected and valued for who they are. This is why we are committed to attracting, developing, and promoting top talent from all backgrounds.
A Commitment to Ethical and Sustainable Practices
At Elgan Pharma, we prioritize ethical practices in every aspect of our work, from the way we conduct our research to the relationships we build with partners. We strive to operate with transparency, accountability, and a strong sense of responsibility toward both people and the environment. Our commitment to integrity, compassion, and innovation guides every decision we make, ensuring that our work benefits society as a whole.
Our Vision for the Future
At Elgan Pharma, we believe that healthcare can be both innovative and compassionate. Our goal is to make a meaningful impact on the lives of preterm infants and their families by providing the care they need to survive and thrive. We are proud to contribute to a more inclusive and compassionate future for healthcare, where every life is valued, and every advancement is a step forward.
